胆汁淤积性肝病的诊治现状及研究方向

于乐成; 陈成伟

doi:10.3969/j.issn.1001-5256.2019.02.001

胆汁淤积性肝病的诊治现状及研究方向

DOI: 10.3969/j.issn.1001-5256.2019.02.001

1. 解放军东部战区总医院/南京中医药大学附属八一医院全军肝病中心
2. 海军军医大学九〇五医院临床肝病研究中心

详细信息

中图分类号: R575
计量
- 文章访问数: 2146
- HTML全文浏览量: 77
- PDF下载量: 609
- 被引次数: 0
出版历程
- 出版日期: 2019-02-20

Current status and research interests of the diagnosis and treatment of cholestatic liver disease

Liver Disease Center of PLA, General Hospital of Eastern Theater Command/Bayi Hospital Affiliated to Nanjing University of Chinese Medicine

摘要

摘要:
胆汁淤积性肝病(CSLD)是指能够引起胆汁淤积的多种肝病的集合和统称,其病因复杂,发病机制有待深入阐明,尚缺乏足够有效的治疗手段。近十余年来对CSLD的多个方面有了较多新认识,为其精准诊治提供了更多层面和更为有效的抓手,同时也反映了许多问题依然悬而未决,亟需继续深入研究。本期重点号从6大方面介绍了有关CSLD的研究进展和存在问题:(1) CSLD的"上升"病理生理学模式;(2)胆汁淤积导致肝纤维化的机制及处置对策;(3)肠肝循环和肠道微生态与CSLD的关系;(4)药物性胆汁淤积的发病机制和诊疗问题;(5)肝衰竭时胆汁淤积的发生机制及处置对策;(6)胆汁淤积性肝病的治疗靶点和药物研发进展等。
- 胆汁淤积 /
- 肝硬化 /
- 肠肝循环 /
- 肝功能衰竭 /
- 诊断 /
- 治疗学 /
- 述评
Abstract:
Cholestatic liver disease ( CSLD) is a group of liver diseases which can cause cholestasis and has a complex etiology. Its pathogenesis remains unclear, and there are still no effective treatment measures. In the recent decade, new achievements have been made on various aspects of CSLD, which provides more help to accurate diagnosis and treatment and reflects many pending issues which need further research. This article introduces the research advances and problems in CSLD from the following six aspects: the“ascending”pathophysiology of CSLD, mechanisms of cholestasis-induced liver fibrosis and related management measures, association of enterohepatic circulation and intestinal microbiota with CSLD, pathogenesis and diagnosis/treatment of drug-induced cholestasis, pathogenesis and management of liver failure-associated cholestasis, and research advances in treatment targets and drug research and development for CSLD.
- cholestasis /
- liver cirrhosis /
- enterohepatic circulation /
- liver failure /
- diagnosis /
- therapeutics /
- editorial

HTML全文

参考文献(37)

[1]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and treatment of cholestasis liver diseases[J].J Clin Hepatol, 2015, 31 (12) :1989-1999. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.胆汁淤积性肝病诊断和治疗共识[J].临床肝胆病杂志, 2015, 31 (12) :1989-1999.

[2]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.

[3]National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association.Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J].J Clin Hepatol, 2018, 34 (5) :939-946. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :939-946.

[4]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of alcohol-related liver disease[J].J Hepatol, 2018, 69 (1) :154-181.

[5]European Association for the Study of the Liver.EASL clinical practice guidelines on hepatitis E virus infection[J].J Hepatol, 2018, 68 (6) :1256-1271.

[6]HOU JL, WANG GQ, WANG FS, et al.Guideline of prevention and treatment for chronic hepatitis B (2015 update) [J].JClin Transl Hepatol, 2017, 5 (4) :297-318.

[7]HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J].Gut, 2018, 67 (9) :1568-1594.

[8]ISAYAMA H, TAZUMA S, KOKUDO N, et al.Clinical guidelines for primary sclerosing cholangitis 2017[J].J Gastroenterol, 2018, 53 (9) :1006-1034.

[9]POLLHEIMER MJ, FICKERT P, STIEGER B.Chronic cholestatic liver diseases:Clues from histopathology for pathogenesis[J].Mol Aspects Med, 2014, 37:35-56.

[10]STICOVA E, JIRSA M, PAWOWSKA J.New Insights in genetic cholestasis:From molecular mechanisms to clinical implications[J].Can J Gastroenterol Hepatol, 2018, 2018:2313675.

[11]JANSEN PL, GHALLAB A, VARTAK N, et al.The ascending pathophysiology of cholestatic liver disease[J].Hepatology, 2017, 65 (2) :722-738.

[12]GONZLEZ-REGUEIRO JA, MORENO-CASTAEDA L, URIBEM, et al.The role of bile acids in glucose metabolism and their relation with diabetes[J].Ann Hepatol, 2017, 16 (Suppl 1) :16-21.

[13]TRAUNER M, CLAUDEL T, FICKERT P, et al.Bile acids as regulators of hepatic lipid and glucose metabolism[J].Dig Dis, 2010, 28 (1) :220-224.

[14]WELLS RG, SCHWABE RF.Origin and function of myofibroblasts in the liver[J].Semin Liver Dis, 2015, 35 (2) :97-106.

[15] LI Y, TANG R, LEUNG PSC, et al.Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J].Autoimmun Rev, 2017, 16 (9) :885-896.

[16]LIU HX, KEANE R, SHENG L, et al.Implications of microbiota and bile acid in liver injury and regeneration[J].J Hepatol, 2015, 63 (6) :1502-1510.

[17]RAMREZ-PREZ O, CRUZ-RAMN V, CHINCHILLA-LPEZ P, et al.The role of the gut microbiota in bile acid metabolism[J].Ann Hepatol, 2017, 16 (Suppl 1) :s15-s20.

[18]DI CIAULA A, GARRUTI G, LUNARDI BACCETTO R, et al.Bile acid physiology[J].Ann Hepatol, 2017, 16 (Suppl 1) :s4-s14.

[19]NIE YF, HU J, YAN XH.Cross-talk between bile acids and intestinal microbiota in host metabolism and health[J].J Zhejiang Univ Sci B, 2015, 16 (6) :436-446.

[20] TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.

[21]MATSUBARA T, LI F, GONZALEZ FJ.FXR signaling in the enterohepatic system[J].Mol Cell Endocrinol, 2013, 368 (1-2) :17-29.

[22]TABIBIAN JH, TALWALKAR JA, LINDOR KD.Role of the microbiota and antibiotics in primary sclerosing cholangitis[J].Biomed Res Int, 2013, 2013:389537.

[23] DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury:The update[J].Int J Mol Sci, 2016, 17 (1) :14.

[24]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guideline for diagnosis and treatment of liver failure[J].J Clin Hepatol, 2019, 35 (1) :38-44. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2018年版) [J].临床肝胆病杂志, 2019, 35 (1) :38-44.

[25]HERNAEZ R, SOLE, MOREAU R, et al.Acute-on-chronic liver failure:An update[J].Gut, 2017, 66 (3) :541-553.

[26]European Association for the Study of the Liver.EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J].J Hepatol, 2017, 66 (5) :1047-1081.

[27]European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.

[28]OLSSON R, BOBERG KM, de MUCKADELL OS, et al.Highdose ursodeoxycholic acid in primary sclerosing cholangitis:A5-year multicenter, randomized, controlled study[J].Gastroenterology, 2005, 129 (5) :1464-1472.

[29] European Association for the Study of the Liver.EASL clinical practice guidelines:The diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.

[30]TRAUNER M, FUCHS CD, HALILBASIC E, et al.New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J].Hepatology, 2017, 65 (4) :1393-1404.

[31]KOWDLEY KV, LUKETIC V, CHAPMAN R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J].Hepatology, 2018, 67 (5) :1890-1902.

[32]CHEUNG AC, LAZARIDIS KN, LARUSSO NF, et al.Emerging pharmacologic therapies for primary sclerosing cholangitis[J].Curr Opin Gastroenterol, 2017, 33 (3) :149-157.

[33]GOLDSTEIN J, LEVY C.Novel and emerging therapies for cholestatic liver diseases[J].Liver Int, 2018, 38 (9) :1520-1535.

[34]de VRIES E, BEUERS U.Management of cholestatic disease in 2017[J].Liver Int, 2017, 37 (Suppl 1) :123-129.

[35] CORPECHOT C, CHAZOUILLRES O, ROUSSEAU A, et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J].N Engl J Med, 2018, 378 (23) :2171-2181.

[36]JONES D, BOUDES PF, SWAIN MG, et al.Seladelpar (MBX-8025) , a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J].Lancet Gastroenterol Hepatol, 2017, 2 (10) :716-726.

[37]BEUERS U, TRAUNER M, JANSEN P, et al.New paradigms in the treatment of hepatic cholestasis:From UDCA to FXR, PXRand beyond[J].J Hepatol, 2015, 62 (Suppl 1) :s25-s37.

施引文献

资源附件(0)

访问统计